CLINICAL_TRIALS
trial_result
· 2021-03-24
Clinical Trial Update: Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB [Phase 2]
Summary
Phase 2 trial assessing adrecizumab in early septic shock patients with high bio-ADM concentration; completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Adrenomed AG | Conditions: Septic Shock | Phase 2 | Status: COMPLETED | Results posted: 2021-03-24